# HRAS Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The HRAS gene encodes a GTPase crucial for cell proliferation and survival, acting as a molecular switch in the MAPK/ERK and PI3K/AKT pathways; germline mutations cause Costello syndrome, while somatic mutations drive cancers like bladder carcinoma and HNSCC. - HRAS exhibits unique C-terminal membrane targeting via dual lipidation (farnesylation and palmitoylation), influencing its compartmentalization and signaling outputs differently from KRAS and NRAS. - Oncogenic HRAS mutations, predominantly at codons G12, G13, and Q61, lock the protein in an active GTP-bound state, impairing GTP hydrolysis and leading to constitutive downstream signaling. - HRAS mutations are found in 10-15% of bladder cancers, often associated with low-grade tumors and a favorable prognosis, and in 4-8% of HNSCCs, where they confer poor survival and resistance to EGFR inhibitors. - Farnesyltransferase inhibitors (FTIs) like tipifarnib have shown promise in HRAS-mutant HNSCC, and downstream inhibitors targeting MEK, ERK, or PI3K/AKT/mTOR pathways are key therapeutic strategies for HRAS-driven malignancies. - Germline HRAS mutations, particularly G12S, are the primary cause of Costello syndrome, a multisystem disorder characterized by facial dysmorphism, cardiac abnormalities, developmental delay, and an increased risk of specific cancers. --- ## Executive Summary & Key Metadata The **HRAS** gene (Harvey rat sarcoma viral oncogene homolog) encodes a 21-kDa membrane-bound GTPase that functions as a molecular switch in signal transduction cascades controlling cellular proliferation, differentiation, and survival. As a founding member of the RAS superfamily, HRAS was among the first human oncogenes identified through its homology to the transforming gene of the Harvey murine sarcoma virus. Germline mutations in HRAS cause Costello syndrome, a rare multisystem RASopathy, while somatic mutations drive a spectrum of malignancies including bladder carcinoma, head and neck squamous cell carcinoma (HNSCC), and cutaneous squamous cell carcinoma. The protein's canonical role in the MAPK/ERK and PI3K/AKT pathways positions it as a critical node in oncogenic signaling networks, yet its unique C-terminal membrane-targeting sequence distinguishes it from KRAS and NRAS in terms of trafficking, compartmentalization, and therapeutic vulnerability. | **Attribute** | **Value** | |---|---| | HGNC Symbol | HRAS | | UniProt Accession | P01112 | | Representative PDB ID | 1QRA (GDP-bound), 1P2S (GTP-bound) | | Chromosomal Locus | 11p15.5 | | Primary Molecular Function | Small GTPase; signal transduction; cell proliferation regulation | | Disease Associations | Costello syndrome; bladder cancer; HNSCC; Spitz nevi; phacomatosis pigmentokeratotica | | Protein Length | 189 amino acids | | Molecular Weight | 21.3 kDa | | Expression Pattern | Ubiquitous; highest in brain, skeletal muscle, and kidney | ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Genomic Context The HRAS gene maps to chromosome **11p15.5**, a gene-dense region characterized by genomic imprinting and frequent loss of heterozygosity (LOH) in embryonal tumors. The locus spans approximately **6.5 kb** of genomic DNA and is oriented on the minus strand (NCBI GRCh38: chr11:522,707–532,637). The chromosomal neighborhood includes the insulin-like growth factor 2 (IGF2) gene, the H19 imprinted transcript, and the ribonuclease/angiogenin inhibitor (RNH1) gene located within 90 kb of HRAS. This clustering has implications for coordinate dysregulation in Wilms tumor and rhabdomyosarcoma, where 11p15.5 LOH frequently encompasses HRAS. The D4 dopamine receptor gene (DRD4) maps proximal to HRAS on 11p, and linkage studies have exploited this proximity for genetic association analyses in neuropsychiatric disorders. In the rat genome, HRAS localizes to chromosome 1q43 by fluorescence in situ hybridization, demonstrating conserved synteny with human 11p15.5. ### 1.2 Promoter Architecture and Regulatory Elements The HRAS promoter is unusual among RAS family members in that it contains **two distinct G-rich elements**, designated hras-1 and hras-2, located upstream of the major transcription start sites. These elements are capable of forming non-canonical DNA secondary structures: - **hras-1**: A G-rich sequence that folds into an antiparallel G-quadruplex (qhras-1) - **hras-2**: A G-rich sequence that forms a parallel G-quadruplex (qhras-2) The complementary C-rich strands of both elements fold into **i-motif structures** (iMs) under acidic conditions in vitro. The i-motif formed by the HRAS C-rich strand (iHRAS: 5'-CGCCCGTGCCCTGCGCCCGCAACCCGA-3') has been crystallographically characterized at high resolution, revealing a unique topology with intercalated hemiprotonated cytosine pairs. These structures are not merely biophysical curiosities; they function as **transcriptional regulatory switches**. The heterogeneous ribonucleoprotein particle A1 (hnRNP A1) binds to and unfolds the i-motif structures, thereby modulating HRAS transcription. Small molecules that stabilize G-quadruplexes, such as the trisubstituted naphthalene derivative, have been shown to suppress HRAS promoter activity in bladder cancer cells. The promoter also contains binding sites for the transcription factor **MAZ** (MYC-associated zinc finger protein), which recognizes GC-rich elements and contributes to basal transcriptional activity. The presence of these quadruplex-forming elements provides a druggable interface for transcriptional inhibition, an approach that has been explored in the context of bladder cancer therapy. ### 1.3 Transcription Factor Binding and Epigenetic Regulation DNase I hypersensitivity mapping has identified multiple regulatory regions flanking the HRAS transcription start sites. The core promoter lacks a canonical TATA box but contains multiple Sp1 binding sites that drive constitutive expression. The 5' untranslated region (UTR) is unusually long (~400 bp) and contains upstream open reading frames (uORFs) that may modulate translational efficiency. **DNA methylation** of the HRAS promoter has been investigated in urocystic tumorigenesis, where altered methylation patterns correlate with tumor grade and stage. Cross-generational effects of alcohol dependence have been shown to influence HRAS and TP53 methylation in offspring, suggesting environmental programming of RAS pathway gene expression. In bladder cancer, promoter hypomethylation may contribute to HRAS overexpression in the absence of activating mutations. ### 1.4 Alternative Splicing and Isoform Diversity The HRAS gene comprises **six exons** (exons 0–5), with the coding sequence distributed across exons 1–5. Alternative splicing generates multiple transcript variants: - **Transcript variant 1** (NM_005343.4): Encodes the canonical 189-amino acid protein; includes all six exons - **Transcript variant 2** (NM_176795.5): Uses an alternative 5' exon, resulting in a distinct 5' UTR but identical open reading frame - **Transcript variant 3** (NM_001130442.3): Contains an additional exon 0, producing a longer 5' UTR All variants encode the identical 189-amino acid protein, as the alternative splicing events occur exclusively in non-coding regions. This conservation of the open reading frame underscores the functional constraint on the HRAS protein sequence. However, the different 5' UTRs may confer differential translational regulation in response to cellular stress or growth factor stimulation. ### 1.5 Polymorphic Variants A well-characterized polymorphism exists at **codon 27** (exon 1), where a single base pair substitution creates or abolishes an NsiI restriction site. This polymorphism (rs12628, c.81T>C, p.His27His) is a synonymous variant that has been extensively studied in association analyses. The HRAS T81C polymorphism has been linked to increased risk of sporadic thyroid cancer in a Kashmiri population, and the same variant has been investigated in breast cancer susceptibility among Jordanian women of Arab descent. The minor allele frequency varies substantially across populations, and the functional significance of this synonymous variant remains debated; it may affect mRNA stability or splicing efficiency. ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The HRAS protein (189 amino acids, ~21.3 kDa) is organized into distinct functional domains that coordinate nucleotide binding, membrane association, and effector interactions. The domain architecture from N-terminus to C-terminus is as follows: | **Domain** | **Residues** | **Function** | |---|---|---| | G-domain (GTPase domain) | 1–166 | Nucleotide binding; GTP hydrolysis; effector interaction | | Switch I | 30–38 | Conformational change upon GTP binding; effector binding | | Switch II | 59–76 | Conformational change; GTPase-activating protein (GAP) interaction | | Hypervariable region (HVR) | 166–189 | Membrane targeting; isoform-specific trafficking | | CAAX box | 186–189 | Prenylation signal (Cys186-A-A-X) | ### 2.2 Three-Dimensional Structure of the G-Domain The G-domain adopts the canonical RAS fold: a six-stranded β-sheet (β1–β6) flanked by five α-helices (α1–α5). This α/β architecture creates a nucleotide-binding pocket with high affinity for GDP and GTP (Kd ≈ 10⁻¹¹ M). The phosphate-binding loop (P-loop, residues 10–17) coordinates the β- and γ-phosphates of the nucleotide through main-chain amide hydrogen bonds and conserved lysine (Lys16) and serine (Ser17) side chains. Two regions undergo dramatic conformational changes upon nucleotide exchange: **Switch I (residues 30–38)**: In the GTP-bound state, Thr35 forms a hydrogen bond with the γ-phosphate, stabilizing the "ON" conformation. This region constitutes the primary effector-binding interface, interacting with the RAS-binding domain (RBD) of effectors such as RAF kinase and PI3K. **Switch II (residues 59–76)**: This region contains the catalytic glutamine (Gln61) and is stabilized by coordination with the bound magnesium ion. GTP hydrolysis is catalyzed through the conserved glutamine, which positions a water molecule for nucleophilic attack on the γ-phosphate. The intrinsic GTPase activity of HRAS is extremely slow (kcat ≈ 0.02 min⁻¹), necessitating GTPase-activating proteins (GAPs) that provide a catalytic arginine "finger" to accelerate hydrolysis by ~10⁵-fold. ### 2.3 Membrane Targeting and the Hypervariable Region The C-terminal hypervariable region (HVR, residues 166–189) is the most divergent region among RAS isoforms and dictates isoform-specific membrane trafficking. HRAS undergoes a three-step post-translational processing: 1. **Farnesylation**: The CAAX motif (Cys186-Val-Leu-Ser) is farnesylated by farnesyltransferase (FTase) at Cys186 2. **Proteolysis**: The AAX tripeptide is cleaved by RAS-converting enzyme 1 (RCE1) 3. **Carboxymethylation**: The C-terminal cysteine is methylated by isoprenylcysteine carboxyl methyltransferase (ICMT) Unlike KRAS4B, which contains a polybasic lysine-rich region that mediates electrostatic interactions with the plasma membrane, HRAS contains a second membrane-targeting signal: **palmitoylation** at Cys181 and Cys184. This dual lipidation (farnesyl + palmitoyl) targets HRAS to the plasma membrane and to endomembrane compartments, including the Golgi apparatus and endosomes. The palmitoylation cycle is dynamic, with depalmitoylation by acyl protein thioesterases (APTs) and repalmitoylation by palmitoyl acyltransferases (PATs) regulating HRAS trafficking between the plasma membrane and Golgi. The unique membrane trafficking of HRAS has functional consequences: endocytosis separates EGF receptors from endogenous fluorescently labeled HRAS, diminishing receptor signaling to MAP kinases in endosomes. This compartmentalized signaling is a distinguishing feature of HRAS compared to KRAS and NRAS. ### 2.4 Structural Basis of Oncogenic Mutations The three most frequent oncogenic mutation sites—Gly12, Gly13, and Gln61—are all located within the nucleotide-binding pocket: - **Gly12**: Located in the P-loop. Substitution with any amino acid other than proline sterically hinders the catalytic arginine finger of GAPs, impairing GTP hydrolysis. Gly12Val is the most common HRAS mutation in Costello syndrome. - **Gly13**: Adjacent to Gly12 in the P-loop; mutations similarly impair GAP-mediated hydrolysis. - **Gln61**: The catalytic residue that positions the nucleophilic water molecule. Substitution (e.g., Gln61Leu, Gln61Arg) abolishes intrinsic and GAP-stimulated GTPase activity, locking the protein in the GTP-bound state. Structural studies of the GTP-bound HRAS-G12V mutant reveal that the valine side chain protrudes into the GAP-binding interface, preventing the conformational changes required for the catalytic machinery to assemble. The result is a protein that is constitutively active but retains near-normal affinity for effectors, driving persistent downstream signaling. ### 2.5 Interactive 3D Visualization For interactive exploration of the HRAS three-dimensional structure, including domain architecture, nucleotide-binding pocket, and mutation hotspots: [Interactive 3D Protein Visualizer: Load HRAS (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P01112) This visualizer enables rotation, zoom, and residue-level inspection of the HRAS structure, with color-coded domains and the ability to highlight specific mutations (G12, G13, Q61) and post-translational modification sites. ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The RAS GTPase Cycle HRAS functions as a binary molecular switch, cycling between an inactive GDP-bound state and an active GTP-bound state. The cycle is controlled by two classes of regulatory proteins: **Guanine nucleotide exchange factors (GEFs)**: Proteins such as SOS1 and SOS2 catalyze the exchange of bound GDP for GTP. GEFs bind to the switch regions, inducing a transient open conformation that allows nucleotide release. Because intracellular GTP concentrations exceed GDP concentrations (~10-fold), the protein re-binds GTP and adopts the active conformation. Growth factor receptor activation recruits GEFs to the plasma membrane via adaptor proteins (GRB2), providing spatial and temporal control of HRAS activation. **GTPase-activating proteins (GAPs)**: Proteins such as p120GAP (RASA1) and neurofibromin (NF1) accelerate the intrinsically slow GTP hydrolysis reaction. GAPs insert a catalytic arginine residue into the active site, stabilizing the transition state and positioning Gln61 for catalysis. Loss of NF1 function in neurofibromatosis type 1 leads to elevated RAS-GTP levels and increased downstream signaling. ### 3.2 Downstream Effector Pathways HRAS-GTP engages multiple downstream effectors, with the most extensively characterized being: #### 3.2.1 RAF-MEK-ERK Pathway (MAPK Cascade) HRAS-GTP binds to the RAS-binding domain (RBD) of RAF kinases (ARAF, BRAF, CRAF), promoting RAF dimerization and activation. Activated RAF phosphorylates and activates MEK1/2, which in turn phosphorylate and activate ERK1/2. ERK translocates to the nucleus and phosphorylates transcription factors including ELK1, c-FOS, and c-JUN, driving expression of genes involved in proliferation and survival. This pathway is the primary driver of HRAS-mediated oncogenesis and is the target of multiple therapeutic interventions. #### 3.2.2 PI3K-AKT-mTOR Pathway HRAS-GTP directly binds the p110 catalytic subunit of phosphoinositide 3-kinase (PI3K), activating the lipid kinase to produce phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 recruits AKT to the plasma membrane, where it is phosphorylated and activated by PDK1 and mTORC2. AKT phosphorylates numerous substrates that promote cell survival (BAD, FOXO), proliferation (p21, p27), and metabolism (GSK3β, TSC2). The PI3K pathway is particularly important in HRAS-driven tumors with concurrent PTEN loss. #### 3.2.3 RALGDS-RAL Pathway HRAS-GTP activates RAL guanine nucleotide dissociation stimulator (RALGDS), which activates the RAL small GTPases (RALA, RALB). RAL proteins regulate vesicle trafficking, actin cytoskeleton organization, and cell migration. This pathway contributes to HRAS-mediated transformation and metastasis. #### 3.2.4 TIAM1-RAC Pathway HRAS-GTP activates TIAM1 (T-lymphoma invasion and metastasis-inducing protein 1), a GEF for the RAC small GTPase. RAC activation promotes actin polymerization, lamellipodia formation, and cell motility. This pathway is particularly relevant to HRAS-driven invasion and metastasis. ### 3.3 Compartmentalized Signaling HRAS signaling is not uniform across cellular membranes. The palmitoylation cycle creates distinct pools of HRAS at the plasma membrane and the Golgi apparatus, each with different signaling outputs. Compartment-specific signaling is regulated by: - **Plasma membrane HRAS**: Primarily activates the RAF-MEK-ERK pathway in response to growth factor stimulation - **Golgi HRAS**: Activates both ERK and PI3K pathways, with distinct kinetics and downstream transcriptional programs Endocytosis of activated EGF receptors separates the receptors from plasma membrane HRAS, diminishing MAP kinase signaling from endosomes. This spatial segregation of signaling components provides an additional layer of regulation that is unique to HRAS among RAS isoforms. ### 3.4 Regulation by MicroRNAs and Long Non-Coding RNAs HRAS expression is post-transcriptionally regulated by multiple microRNAs: - **miR-210**: Differentially expressed during follicular-luteal transition, regulates granulosa cell function by targeting HRAS and EFNA3 - **miR-1968-5p**: Part of the 2210408F21Rik/miR-1968-5p/Hras ceRNA axis that regulates synapse-related proteins in depressive-like behaviors Long non-coding RNAs (lncRNAs) also modulate HRAS expression through competitive endogenous RNA (ceRNA) mechanisms. In systemic lupus erythematosus, differentially expressed lncRNAs are associated with altered HRAS mRNA levels. ### 3.5 Protein-Protein Interaction Network The HRAS interaction network is extensive, with over 100 documented binding partners in BioGRID. Key interactions include: | **Interaction Partner** | **Interaction Type** | **Functional Consequence** | |---|---|---| | RAF1 (CRAF) | Effector binding | MAPK pathway activation | | PIK3CA (p110α) | Effector binding | PI3K pathway activation | | RALGDS | Effector binding | RAL pathway activation | | SOS1 | GEF | Nucleotide exchange | | RASA1 (p120GAP) | GAP | GTP hydrolysis | | NF1 (Neurofibromin) | GAP | GTP hydrolysis | | RIN1 | Effector | Endocytosis; integrin trafficking | | DYRK2 | Kinase | Phosphorylation; degradation | The interaction with RIN1 is particularly relevant to Costello syndrome, where the HRAS p.Gly12Ser mutation affects RIN1-mediated integrin trafficking in keratinocytes, contributing to the cutaneous manifestations of the disorder. DYRK2 promotes the degradation of HRAS (and MYC), and DYRK2 gene transfer suppresses hepatocarcinogenesis by promoting this degradation. ### 3.6 Signaling in Development and Differentiation HRAS signaling is essential for normal development. In the brain, HRAS and KRAS proto-oncogenes are induced by reactive oxygen species in primary astrocytes, suggesting a role in oxidative stress responses. The high expression of p21Ras in the brain underscores its importance in neuronal function and plasticity. In the ovary, HRAS is a target of miR-210 during follicular-luteal transition, where it regulates granulosa cell function. This demonstrates the broad physiological roles of HRAS beyond its oncogenic functions. ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Somatic Mutations in Cancer HRAS is mutated in approximately 3–5% of human cancers, with significant variation by tumor type. The mutation spectrum is dominated by missense mutations at three codons: G12, G13, and Q61. #### 4.1.1 Bladder Cancer HRAS mutations occur in **10–15%** of bladder cancers, making it one of the most frequently mutated genes in this malignancy. The mutations are predominantly at codon 12 (G12V, G12D, G12C) and codon 61 (Q61R, Q61L). HRAS mutations are associated with: - **Low-grade, non-muscle-invasive tumors**: HRAS mutations are more frequent in Ta/T1 tumors than in muscle-invasive disease - **Favorable prognosis**: Patients with HRAS-mutant tumors may have better outcomes than those with TP53 mutations - **FGFR3 co-mutation**: HRAS and FGFR3 mutations are mutually exclusive in most bladder cancer series, suggesting functional redundancy The UroSEEK gene panel, which includes HRAS, has been developed for non-invasive detection and surveillance of bladder cancer using urine samples. The panel detects alterations in 11 genes, including HRAS, with high sensitivity and specificity. #### 4.1.2 Head and Neck Squamous Cell Carcinoma HRAS mutations are present in **4–8%** of HNSCCs. The mutations are predominantly at codon 61 (Q61R, Q61K, Q61L) and are associated with: - **Poor survival**: HRAS mutations confer worse overall survival in HNSCC patients - **Resistance to EGFR inhibitors**: HRAS-mutant HNSCC cells are resistant to erlotinib and cetuximab - **HPV-negative tumors**: HRAS mutations are more frequent in HPV-negative HNSCCs The Cancer Genome Atlas (TCGA) comprehensive genomic characterization of HNSCC identified HRAS mutations as a recurrent alteration, particularly in tumors with wild-type TP53. Whole-exome sequencing has revealed that HRAS mutations may also mediate resistance to metronomic chemotherapy in HNSCC. #### 4.1.3 Cutaneous Squamous Cell Carcinoma and Spitz Nevi HRAS mutations are found in a subset of cutaneous squamous cell carcinomas and are particularly characteristic of **Spitz nevi**, where they occur in up to 20% of cases. The mutations in Spitz nevi are typically at codon 61 and are associated with distinctive histopathological features, including epithelioid morphology. HRAS mutations in Spitz nevi are often accompanied by copy number increases of chromosome 11p. #### 4.1.4 Thyroid Cancer HRAS mutations are present in **1–3%** of papillary thyroid carcinomas and a higher proportion of follicular thyroid carcinomas. In thyroid nodules, HRAS mutations are associated with: - **Follicular-patterned tumors**: HRAS mutations are more common in follicular adenomas and follicular carcinomas than in papillary carcinomas - **Indeterminate cytology**: HRAS mutation testing is used in the molecular classification of indeterminate thyroid nodules - **TERT promoter co-mutation**: HRAS mutations co-occur with TERT promoter mutations in aggressive thyroid cancers A study of Indonesian papillary thyroid carcinoma patients found that HRAS mutations were present in a subset of cases, with BRAFV600E being the most common mutation. The absence of RAS mutations distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. #### 4.1.5 Other Malignancies HRAS mutations have been identified in: - **Breast adenomyoepitheliomas**: Recurrent hotspot mutations at HRAS Q61 are found in these rare tumors, often co-occurring with PI3K-AKT pathway mutations - **Pheochromocytomas and paragangliomas**: HRAS mutations are present in ~5% of these neuroendocrine tumors - **Oral squamous cell carcinoma**: HRAS mutations are found in a subset of cases, with novel mutations reported in Greek populations and Japanese patients - **Penile cancer**: HRAS mutations are present in ~10% of cases - **Rhabdomyosarcoma**: HRAS mutations are found in fusion-negative tumors - **Non-small cell lung cancer**: HRAS mutations are rare (~0.2–0.8%), predominantly at codon 61 - **Gastric carcinoma**: HRAS promotes cancer cell aggressiveness - **Ameloblastoma**: HRAS mutations are rare but present in a subset of cases ### 4.2 Germline Mutations and RASopathies #### 4.2.1 Costello Syndrome Costello syndrome (OMIM 218040) is a rare congenital disorder caused by heterozygous germline mutations in HRAS. The syndrome is characterized by: - **Facial dysmorphism**: Coarse facies, epicanthal folds, depressed nasal bridge, thick lips - **Cutaneous manifestations**: Loose, redundant skin; deep palmar and plantar creases; papillomata - **Cardiac abnormalities**: Hypertrophic cardiomyopathy, multifocal atrial tachycardia - **Developmental delay**: Intellectual disability, delayed motor milestones - **Growth failure**: Postnatal growth retardation, feeding difficulties - **Increased cancer risk**: Predisposition to rhabdomyosarcoma, bladder cancer, and neuroblastoma Approximately **80–90%** of Costello syndrome cases are caused by the c.34G>A (p.Gly12Ser) mutation. Other recurrent mutations include p.Gly12Asp, p.Gly12Ala, and p.Gly12Val. The p.Gly12Val mutation has been associated with a severe fetal phenotype, including polyhydramnios, cystic hygroma, and neuromuscular spindle excess. The cardiac phenotype of Costello syndrome has been modeled in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). HRAS-mutant cardiomyocytes exhibit abnormal calcium handling and action potential properties that underlie the development of multifocal atrial tachycardia. This model provides a platform for testing therapeutic interventions for the arrhythmias associated with Costello syndrome. #### 4.2.2 Schimmelpenning-Feuerstein-Mims Syndrome Schimmelpenning-Feuerstein-Mims (SFM) syndrome is a mosaic RASopathy caused by postzygotic HRAS mutations. The syndrome is characterized by: - **Nevus sebaceous**: Large, linear sebaceous nevi following Blaschko's lines - **Extracutaneous abnormalities**: Central nervous system, ocular, and skeletal defects - **Somatic mosaicism**: Mutations are present in affected tissues but not in the germline Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. The mutations are typically at codon 12 or 13 and are present in the affected skin but absent from blood. #### 4.2.3 Phacomatosis Pigmentokeratotica Phacomatosis pigmentokeratotica (PPK) is a rare epidermal nevus syndrome characterized by the co-occurrence of speckled lentiginous nevus (SLN) and nevus sebaceous (NS). The condition is caused by a postzygotic HRAS mutation in a multipotent progenitor cell. The first case of Chinese PPK was diagnosed by a missense HRAS mosaicism. #### 4.2.4 Other RASopathy Phenotypes HRAS mutations have been associated with: - **Cutaneous skeletal hypophosphatemia syndrome**: A mosaic HRAS mutation was identified in a patient with this rare disorder - **Left ventricular hypertrophy**: A novel HRAS mutation independently contributes to LVH in a family with a known MYH7 mutation - **Congenital muscular dystrophy phenotype**: A 5-year-old girl with neuromuscular spindle excess caused by an HRAS mutation ### 4.3 In Silico Prediction of Pathogenic Variants Computational approaches have been employed to predict the deleterious effects of HRAS nsSNPs: - **Machine learning approaches**: Chai et al. (2022) conducted a machine-learning approach to identify high-risk predictive alleles of HRAS that could predispose to cancer - **Structural analysis**: Ali et al. (2023) predicted the effects of rare genetic variants on oncogenic signaling pathways through computational analysis of HRAS protein function - **SNP analysis**: Dakshitha et al. (2024) computationally explored single-nucleotide polymorphisms in the human HRAS gene These in silico approaches integrate sequence conservation, structural context, and biophysical properties to prioritize variants for functional validation. ### 4.4 Mutational Signatures and Environmental Exposures HRAS mutations in certain cancers are associated with specific environmental exposures: - **Aristolochic acid**: Exposure to aristolochic acid is associated with HRAS and TP53 mutations in urothelial carcinoma after kidney transplantation - **Cisplatin adducts**: DNA polymerase beta bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene, providing a mechanism for cisplatin-induced mutagenesis - **Alcohol dependence**: Cross-generational effects of alcohol dependence influence HRAS and TP53 methylation in offspring ### 4.5 HRAS in Non-Cancer Diseases Beyond cancer and RASopathies, HRAS has been implicated in: - **Autism**: Association studies have examined two markers of the HRAS gene in autism - **Depression**: The 2210408F21Rik/miR-1968-5p/Hras axis regulates synapse-related proteins in depressive-like behaviors - **Sleep disorders**: Increased sleep spindle activity is observed in patients with Costello syndrome ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Oncoproteins and HRAS Cooperation The HRAS gene was originally identified through its homology to the transforming gene of the Harvey murine sarcoma virus. The viral oncoprotein v-H-Ras differs from cellular HRAS by two amino acid substitutions (Gly12Arg and Thr59Ile) that render it constitutively active. This viral acquisition of a cellular oncogene exemplifies the mechanism by which retroviruses can hijack host signaling pathways. ### 5.2 Human Papillomavirus (HPV) Interactions In HPV-positive oropharyngeal squamous cell carcinoma, the mutational landscape differs from HPV-negative tumors. While HRAS mutations are less frequent in HPV-positive tumors, the PI3K pathway is frequently activated through PIK3CA mutations and PTEN loss. The viral E6 and E7 oncoproteins degrade p53 and RB, respectively, cooperating with RAS pathway activation to drive transformation. The absence of HRAS mutations in HPV-positive tumors suggests that viral oncoproteins may substitute for RAS pathway activation. ### 5.3 DNA Damage and Mutagenesis The HRAS gene is a target for environmental mutagens that induce DNA damage: - **Cisplatin**: DNA polymerase beta bypasses a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene. This translesion synthesis can introduce mutations at this critical codon, potentially activating the oncogene. - **Reactive oxygen species**: ROS induce early and late expression of KRAS and HRAS proto-oncogenes in primary astrocytes, suggesting a role in oxidative stress responses. ### 5.4 Viral Vectors and HRAS Transgenic Models Transgenic mice harboring the human prototype c-HRAS gene have been developed for rapid carcinogenicity testing. These mice are sensitive to chemical carcinogens and provide a model for assessing the carcinogenic potential of environmental agents. The MMTV-Hras transgenic mouse model has been used to study the effects of p53 mutations on salivary gland tumors. Lentiviral vectors expressing HRAS-G12V have been used to induce high-grade gliomas in rats, in combination with PDGFB, AKT, and IDH1-R132H. These models recapitulate the molecular heterogeneity of human gliomas and provide platforms for testing therapeutic interventions. ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Direct HRAS Inhibitors For decades, RAS proteins were considered "undruggable" due to their picomolar affinity for GTP and the absence of deep hydrophobic pockets suitable for small-molecule binding. However, recent advances have begun to change this paradigm: #### 6.1.1 Farnesyltransferase Inhibitors (FTIs) Because HRAS is farnesylated (unlike KRAS and NRAS, which can be geranylgeranylated as an alternative), FTIs were initially developed as HRAS-specific inhibitors. Tipifarnib (R115777) and lonafarnib (SCH66336) showed preclinical activity against HRAS-mutant tumors. However, clinical trials demonstrated limited efficacy, partly due to alternative prenylation of KRAS and NRAS and compensatory signaling pathways. Tipifarnib has shown renewed promise in HRAS-mutant HNSCC, with clinical trials demonstrating objective responses in a subset of patients. The compound is currently being evaluated in HRAS-mutant malignancies, including HNSCC and thyroid cancer. #### 6.1.2 Direct RAS Inhibitors The success of allele-specific KRAS G12C inhibitors (sotorasib, adagrasib) has spurred efforts to develop HRAS-specific inhibitors. However, HRAS G12C mutations are rare, and no HRAS G12C inhibitor has been approved. The structural differences between HRAS and KRAS in the switch II pocket may allow for the development of HRAS-selective inhibitors, but this remains an active area of research. ### 6.2 Downstream Pathway Inhibitors Given the difficulty of directly targeting HRAS, therapeutic strategies have focused on downstream effectors: #### 6.2.1 MEK Inhibitors MEK1/2 inhibitors (trametinib, selumetinib, cobimetinib) block the MAPK pathway downstream of HRAS. These agents have shown activity in RASopathies and RAS-mutant cancers: - **Trametinib**: Approved for BRAF-mutant melanoma; being evaluated in RAS-mutant cancers - **Selumetinib**: Approved for neurofibromatosis type 1; being evaluated in RASopathies In Costello syndrome, MEK inhibition has been proposed as a therapeutic strategy to ameliorate the developmental and cardiac phenotypes. #### 6.2.2 ERK Inhibitors ERK1/2 inhibitors (ulixertinib, ravoxertinib) target the terminal kinase in the MAPK pathway. These agents may overcome resistance mechanisms that limit the efficacy of MEK inhibitors. #### 6.2.3 PI3K/AKT/mTOR Inhibitors Inhibitors of the PI3K-AKT-mTOR pathway (alpelisib, everolimus) may be effective in HRAS-mutant tumors with concurrent PI3K pathway activation. The frequent co-occurrence of HRAS and PIK3CA mutations in breast adenomyoepitheliomas suggests that dual pathway inhibition may be required. #### 6.2.4 EGFR Inhibitors HRAS mutations confer resistance to EGFR inhibitors (cetuximab, erlotinib) in HNSCC. This resistance is mediated by constitutive activation of the MAPK pathway downstream of EGFR. Therefore, HRAS mutation status is an important biomarker for patient selection in EGFR-targeted therapy. ### 6.3 Combination Strategies Rational combination strategies for HRAS-mutant cancers include: - **MEK inhibitor + EGFR inhibitor**: To block both the MAPK pathway and upstream receptor signaling - **MEK inhibitor + PI3K inhibitor**: To block parallel survival pathways - **Farnesyltransferase inhibitor + MEK inhibitor**: To target both HRAS membrane localization and downstream signaling ### 6.4 Natural Products and Repurposed Drugs Several natural products have shown activity against HRAS-mutant cells: - **Pterostilbene**: Sensitizes cisplatin-resistant human bladder cancer cells with oncogenic HRAS - **Ginsenoside Rh2(S)**: Maintains cytoskeleton homeostasis and inhibits pyroptosis to resist cisplatin-induced cardiotoxicity through the FGFR1/HRAS axis ### 6.5 Gene Therapy and RNA-Based Approaches - **DYRK2 gene transfer**: Suppresses hepatocarcinogenesis by promoting the degradation of MYC and HRAS - **siRNA/shRNA approaches**: Knockdown of HRAS expression in cancer cells inhibits proliferation and induces apoptosis - **Antisense oligonucleotides**: Targeting HRAS mRNA for degradation ### 6.6 Immunotherapy and Vaccines - **Peptide vaccines**: A multi-valent epitope vaccine targeting HRAS oncogene has been designed for squamous cell carcinoma - **Adoptive cell therapy**: Targeting HRAS-mutant neoantigens with engineered T cells ### 6.7 Photodynamic Therapy Photodynamic therapy (PDT) affects the expression of HRAS, NRAS, and caspase 3 genes at the mRNA level, inducing apoptosis in HNSCC cell lines. This approach may be particularly relevant for HRAS-mutant tumors. ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/Identifier** | **URL** | |---|---|---| | NCBI Gene | 3265 | https://www.ncbi.nlm ## Related Clinical & Scientific Guides * [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway) * [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway) * [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)